Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
INSY's Cash-to-Debt is ranked higher than
95% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. INSY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INSY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
INSY's Equity-to-Asset is ranked higher than
64% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. INSY: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
INSY' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.45  Med: 0.79 Max: 0.98
Current: 0.76
-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
95% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s Interest Coverage Range Over the Past 10 Years
Min: 34.27  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 6.81
Beneish M-Score: -2.60
WACC vs ROIC
18.13%
26.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 13.08
INSY's Operating Margin % is ranked higher than
82% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. INSY: 13.08 )
Ranked among companies with meaningful Operating Margin % only.
INSY' s Operating Margin % Range Over the Past 10 Years
Min: -324863.64  Med: -151.46 Max: 32.79
Current: 13.08
-324863.64
32.79
Net Margin % 8.71
INSY's Net Margin % is ranked higher than
80% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. INSY: 8.71 )
Ranked among companies with meaningful Net Margin % only.
INSY' s Net Margin % Range Over the Past 10 Years
Min: -301890.91  Med: -157.52 Max: 40.67
Current: 8.71
-301890.91
40.67
ROE % 9.46
INSY's ROE % is ranked higher than
86% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. INSY: 9.46 )
Ranked among companies with meaningful ROE % only.
INSY' s ROE % Range Over the Past 10 Years
Min: -130.7  Med: -46.69 Max: 545.67
Current: 9.46
-130.7
545.67
ROA % 7.13
INSY's ROA % is ranked higher than
89% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. INSY: 7.13 )
Ranked among companies with meaningful ROA % only.
INSY' s ROA % Range Over the Past 10 Years
Min: -118.94  Med: -54.65 Max: 67.69
Current: 7.13
-118.94
67.69
ROC (Joel Greenblatt) % 84.19
INSY's ROC (Joel Greenblatt) % is ranked higher than
93% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. INSY: 84.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2087.93  Med: -1261.67 Max: 203.36
Current: 84.19
-2087.93
203.36
3-Year Revenue Growth Rate 99.00
INSY's 3-Year Revenue Growth Rate is ranked higher than
94% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INSY: 99.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -60.75 Max: 500
Current: 99
0
500
GuruFocus has detected 3 Warning Signs with Insys Therapeutics Inc $INSY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INSY Guru Trades in Q1 2016

Joel Greenblatt 1,065,310 sh (+28.27%)
Paul Tudor Jones Sold Out
John Hussman Sold Out
» More
Q2 2016

INSY Guru Trades in Q2 2016

Jim Simons 229,600 sh (New)
Joel Greenblatt 943,960 sh (-11.39%)
» More
Q3 2016

INSY Guru Trades in Q3 2016

Lee Ainslie 203,860 sh (New)
Steven Cohen 367,143 sh (New)
Paul Tudor Jones 13,398 sh (New)
Jim Simons 264,500 sh (+15.20%)
Joel Greenblatt 327,060 sh (-65.35%)
» More
Q4 2016

INSY Guru Trades in Q4 2016

Arnold Schneider 44,973 sh (New)
Paul Tudor Jones 42,405 sh (+216.50%)
Lee Ainslie 274,211 sh (+34.51%)
Steven Cohen 348,627 sh (-5.04%)
Jim Simons 241,500 sh (-8.70%)
Joel Greenblatt 207,055 sh (-36.69%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ARDX, NAS:JNCE, OTCPK:PHMMF, NYSE:MYOV, NAS:ASND, NAS:NDRM, NAS:ACRS, OTCPK:IPHYF, NAS:VSAR, NAS:ACIU, NAS:MGNX, NAS:ITCI, NAS:ADRO, NAS:LJPC, NAS:BCRX, OTCPK:SXMDF, NAS:PGNX, NAS:TGTX, NAS:VNDA, NAS:ANIK » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. Its two marketed products include Subsys and Dronabinol SG Capsule.

Insys Therapeutics is a biotechnology company that develops and commercializes innovative drugs and novel drug delivery systems. The company maintains cannabinoid formulation and manufacturing, as well as sublingual spray drug delivery technology, to develop a portfolio of differentiated, wholly owned product candidates. Insys continues to specifically target oncology healthcare providers and practices. The company's sublingual spray delivery system is sourced, manufactured, and assembled by multiple third parties across the United States and Europe.

Ratios

vs
industry
vs
history
PE Ratio 32.95
INSY's PE Ratio is ranked lower than
53% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. INSY: 32.95 )
Ranked among companies with meaningful PE Ratio only.
INSY' s PE Ratio Range Over the Past 10 Years
Min: 16.11  Med: 32.78 Max: 2102.86
Current: 32.95
16.11
2102.86
Forward PE Ratio 43.29
INSY's Forward PE Ratio is ranked lower than
81% of the 78 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. INSY: 43.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.95
INSY's PE Ratio without NRI is ranked lower than
52% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. INSY: 32.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
INSY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.91  Med: 32.78 Max: 736
Current: 32.95
15.91
736
Price-to-Owner-Earnings 19.44
INSY's Price-to-Owner-Earnings is ranked higher than
62% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 26.25 vs. INSY: 19.44 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INSY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.44  Med: 24.97 Max: 817.78
Current: 19.44
12.44
817.78
PB Ratio 2.71
INSY's PB Ratio is ranked higher than
63% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. INSY: 2.71 )
Ranked among companies with meaningful PB Ratio only.
INSY' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 1.86 Max: 19.87
Current: 2.71
0.06
19.87
PS Ratio 2.76
INSY's PS Ratio is ranked higher than
83% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. INSY: 2.76 )
Ranked among companies with meaningful PS Ratio only.
INSY' s PS Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2170 Max: 29890
Current: 2.76
1.74
29890
Price-to-Free-Cash-Flow 15.47
INSY's Price-to-Free-Cash-Flow is ranked higher than
66% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 22.69 vs. INSY: 15.47 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INSY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.4  Med: 37.58 Max: 167.27
Current: 15.47
11.4
167.27
Price-to-Operating-Cash-Flow 12.76
INSY's Price-to-Operating-Cash-Flow is ranked higher than
70% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 23.59 vs. INSY: 12.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INSY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.05  Med: 28.34 Max: 1288.75
Current: 12.76
10.05
1288.75
EV-to-EBIT 15.42
INSY's EV-to-EBIT is ranked higher than
55% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. INSY: 15.42 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.9  Med: 0.7 Max: 82.9
Current: 15.42
-130.9
82.9
EV-to-EBITDA 13.23
INSY's EV-to-EBITDA is ranked higher than
55% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. INSY: 13.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -228.4  Med: 0.7 Max: 72.1
Current: 13.23
-228.4
72.1
Current Ratio 3.07
INSY's Current Ratio is ranked lower than
62% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. INSY: 3.07 )
Ranked among companies with meaningful Current Ratio only.
INSY' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 5.94 Max: 318.82
Current: 3.07
0.14
318.82
Quick Ratio 2.70
INSY's Quick Ratio is ranked lower than
62% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INSY: 2.70 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.94 Max: 318.82
Current: 2.7
0.06
318.82
Days Inventory 564.43
INSY's Days Inventory is ranked lower than
96% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. INSY: 564.43 )
Ranked among companies with meaningful Days Inventory only.
INSY' s Days Inventory Range Over the Past 10 Years
Min: 169.77  Med: 398.57 Max: 1095
Current: 564.43
169.77
1095
Days Sales Outstanding 44.94
INSY's Days Sales Outstanding is ranked higher than
63% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. INSY: 44.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67  Med: 48.55 Max: 72.85
Current: 44.94
0.67
72.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.00
INSY's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INSY: -37.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -269.6  Med: -17.5 Max: 49.5
Current: -37
-269.6
49.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.58
INSY's Price-to-Net-Cash is ranked lower than
63% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. INSY: 8.58 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 8.99 Max: 69.25
Current: 8.58
1
69.25
Price-to-Net-Current-Asset-Value 4.86
INSY's Price-to-Net-Current-Asset-Value is ranked higher than
57% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. INSY: 4.86 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.98  Med: 7.29 Max: 91.93
Current: 4.86
0.98
91.93
Price-to-Tangible-Book 2.72
INSY's Price-to-Tangible-Book is ranked higher than
70% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. INSY: 2.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 5.74 Max: 84.45
Current: 2.72
0.55
84.45
Price-to-Intrinsic-Value-Projected-FCF 1.77
INSY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.22 vs. INSY: 1.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INSY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.72  Med: 6.03 Max: 41.26
Current: 1.77
1.72
41.26
Price-to-Graham-Number 1.99
INSY's Price-to-Graham-Number is ranked higher than
60% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.54 vs. INSY: 1.99 )
Ranked among companies with meaningful Price-to-Graham-Number only.
INSY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.78  Med: 4.01 Max: 20.1
Current: 1.99
1.78
20.1
Earnings Yield (Greenblatt) % 6.51
INSY's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. INSY: 6.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 121.45 Max: 2305
Current: 6.51
1.2
2305

More Statistics

Revenue (TTM) (Mil) $275.4
EPS (TTM) $ 0.31
Beta2.08
Short Percentage of Float103.43%
52-Week Range $8.70 - 20.98
Shares Outstanding (Mil)71.77

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 237 232 305 396
EPS ($) 0.29 0.23 0.79 1.50
EPS without NRI ($) 0.29 0.23 0.79 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
65.00%
Dividends per Share ($)
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017 
America’s War on Drugs Mar 07 2017 
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
Gurus' Worst Recent Investments Feb 15 2017 
Weeding Out the Winners in Race for Cannabis-Based Drugs Jun 05 2016 
Comments on the Blockbuster Valeant Conference Call Oct 30 2015 

More From Other Websites
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Mar 21 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of INSYS Therapeutics, Inc. of a Class... Mar 20 2017
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Insys... Mar 17 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Mar 17 2017
Pomerantz Law Firm Announces the Filing of a Class Action against INSYS Therapeutics, Inc. and... Mar 17 2017
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Insys... Mar 16 2017
Insys Falls on Earnings Delay Mar 16 2017
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Insys Therapeutics, Inc. Investors Mar 16 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving... Mar 16 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INSYS Therapeutics,... Mar 16 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INSYS... Mar 16 2017
INSYS Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : INSY-US : March... Mar 16 2017
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 15 2017
Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results Mar 15 2017
5 Earnings Short-Squeeze Plays: Tiffany, Athene and More Mar 14 2017
Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)